Brief: Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis

Geron

06/12/2023 13:12

Dec 6 (Reuters) - Geron Corp  GERN.O :
    * GERON ANNOUNCES FIFTY PERCENT ENROLLMENT IN THE PHASE 3
IMPACTMF
CLINICAL TRIAL EVALUATING IMETELSTAT IN PATIENTS WITH
RELAPSED/REFRACTORY MYELOFIBROSIS
    * GERON CORP - AN INTERIM ANALYSIS IS EXPECTED IN FIRST HALF
OF
2025, WITH A FINAL ANALYSIS EXPECTED IN FIRST HALF OF 2026

Source text for Eikon:  ID:nBw4vW1GLa 
Further company coverage:  GERN.O 

 ((Reuters.Briefs@thomsonreuters.com;))